Printer Friendly


 SAN DIMAS, Calif., Oct. 19 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today announced that Dr. Jane L. Delgado has been elected to the company's board of directors. Dr. Delgado is president and chief executive officer of the National Coalition of Hispanic Health and Human Services Organizations (COSSMHO) in Washington. She previously held the positions of health policy advisor, senior program analyst and senior social scientist at the U.S. Department of Health & Human Services.
 Dr. Delgado serves on several advisory councils including the Robert Wood Johnson Foundation Fighting Back Drug Abuse in America and is chairperson of the National Health Council. She has served on the Advisory Committee on the Food and Drug Administration, National Council on Patient Information and Education, Office of Technology Assessment Advisory Panel on Technology, Insurance and the Health Care System, and NIH Human Fetal Tissue Transplantation Research Panel. Dr. Delgado holds a Ph.D. in clinical psychology from the State University of New York at Stony Brook.
 "We are very pleased to have Dr. Jane Delgado join our board of directors," said Roger J. Crossley, chairman, president and chief executive officer of Vestar. "We look forward to benefitting from her expertise and perspectives on issues such as AIDS education, balancing healthcare cost management and also minority healthcare."
 Vestar, Inc. develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections. Since 1989, Vestar has marketed in Europe a liposomal formulation of amphotericin B, called AmBisome(R), to treat systemic fungal infections. DaunoXome(R), Vestar's second major product, for the treatment of AIDS-associated Kaposi's sarcoma, is in Phase III clinical trials. Vestar's third major product, MiKasome, a liposomal formulation of the antibiotic amikacin to treat tuberculosis and mycobacterium avium, is in Phase I clinical trials. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, lipid prodrug technology for the development of anti-viral and anti-cancer compounds and new synthetic anti-cancer molecules.
 -0- 10/19/93
 /CONTACT: Michael E. Hart of Vestar, 909-394-4119/

CO: Vestar, Inc. ST: California IN: MTC SU: PER

TW-LG -- NY082 -- 4093 10/19/93 15:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters